List view / Grid view
Prof. Klaus Dugi serves as Corporate Senior Vice President of Medicine and Chief Medical Officer at Boehringer Ingelheim GmbH.
"We welcome the positive conclusions reached..."
5 November 2012 | By Boehringer Ingelheim
"We welcome the positive conclusions reached..."
Patients and physicians may have several innovative respiratory treatments available…
31 October 2012 | By Boehringer Ingelheim
Patients and physicians may have several innovative respiratory treatments available in the coming years...
Boehringer Ingelheim and Eli Lilly and Company today announced that…
26 October 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company today announced that the European Commission has approved an expanded therapeutic indication for the DPP-4 inhibitor Trajenta® (linagliptin) to include use in combination with insulin in adults with Type 2 Diabetes.
Results of a pooled analysis...
2 October 2012 | By Boehringer Ingelheim
Results of a pooled analysis...
Boehringer Ingelheim and Eli Lilly and Company today announced results…
2 October 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company today announced results from a large Phase III study and three pooled analyses of Phase III data presented at the 48th European Association for the Study of Diabetes (EASD) Annual Meeting, which support Trajenta® (linagliptin) as effective and well-tolerated for patients with type…
Boehringer Ingelheim and Eli Lilly and Company today announced that…
24 September 2012 | By Boehringer Ingelheim / Eli Lilly and Company
Boehringer Ingelheim and Eli Lilly and Company today announced that they have received a Positive Opinion from the European Medicines Agency’s (EMA) medicinal committee recommending expanding the therapeutic indication for the DPP-4 inhibitor Trajenta® (linagliptin). If approved by the European Commission, this will expand the indicated use of Trajenta® by…
Submission of a MAA to the EMA for approval of…
20 September 2012 | By Boehringer Ingelheim
Submission of a MAA to the EMA for approval of afatinib*...
“These results exceeded our expectations..."
3 September 2012 | By Boehringer Ingelheim
“These results exceeded our expectations..."
New one-year follow-up results from the global RE-LY AF registry...
29 August 2012 | By Boehringer Ingelheim
New one-year follow-up results from the global RE-LY AF registry...
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) received…
25 July 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) received Marketing Authorisation from the European Commission for Jentadueto® which combines the DPP-4 inhibitor, linagliptin and metformin in a single tablet. 1 Linagliptin/metformin hydrochloride (HCl) will provide a new, single-tablet treatment option, taken twice-daily, for adults with Type 2 Diabetes. 1
FX125L is a small molecule...
23 July 2012 | By Boehringer Ingelheim
FX125L is a small molecule...
The design of the RE-ALIGN study published...
20 June 2012 | By Boehringer Ingelheim
The design of the RE-ALIGN study published...
Boehringer Ingelheim has updated the US prescribing information for Pradaxa®...
6 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim has updated the US prescribing information for Pradaxa®...
LUX-Lung 3 results highlighted at the official ASCO Press Conference...
4 June 2012 | By Boehringer Ingelheim
LUX-Lung 3 results highlighted at the official ASCO Press Conference...
Boehringer Ingelheim announces a new partnership with ammado...
1 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim announces a new partnership with ammado...
